Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mimbari who wrote (12225)	7/13/2013 1:45:29 PM
From: NTTG	1 Recommendation Recommended By Pogeu Mahone Read Replies (1) \| Respond to of 13111

You might want to think about reading the poster before responding...the tables are clearly labeled TARGET LESION RESPONSE RATES and BYSTANDER LESION RESPONSE RATES. The target lesions (the numbers I provided you), are the lesions that were directly injected with the cytotoxic drug RB, READ THE STUDY PROTOCOL and the EXAMPLES OF CLINICAL RESPONSE. What comparative IL lesion data are you referring to, there is none in this study? The target lesions that responded to RB responded quickly; read the graph for PROGRESSION FREE SURVIVAL of the TARGET LESION for tumors with SD or better response, compared to tumors that did not respond. Responses and failures are easily seen in the 12 week window There is nothing misleading about poor response of stage IV target lesions to the direct injection of a cytotoxic drug, there is only one conclusion,,,RB did not kill those lesions.